Leave Your Message
-
Phone
-
E-mail
-
Whatsapp
-
Wechat
The medical industry demands the highest standards of safety, hygiene, and reliability when it comes to packaging materials. Cold PVC film has emerged as a cornerstone solution for pharmaceutical and medical device packaging, offering exceptional barrier properties, biocompatibility, and versatility. As healthcare systems worldwide evolve and regulatory requirements become more stringent, cold PVC film technology continues to advance, meeting the complex needs of modern medical applications.
Cold PVC film, also known as cold-forming aluminum/PVC laminate, represents a sophisticated packaging solution specifically engineered for the medical and pharmaceutical industries. Unlike traditional thermoforming PVC, cold PVC film is formed at room temperature, preserving the integrity of sensitive medications and medical devices. This process involves a multi-layer laminate structure typically consisting of polyvinyl chloride (PVC), polyethylene (PE), and aluminum foil, creating an impermeable barrier against moisture, oxygen, and light.
The composition of medical-grade cold PVC film is meticulously designed to meet international standards such as USP Class VI, ISO 15378, and EU Pharmacopoeia requirements. The PVC layer provides excellent formability and seal strength, while the aluminum layer offers superior barrier properties. The polyethylene layer serves as a heat-sealable component, ensuring hermetic sealing that protects pharmaceutical products throughout their shelf life.
Cold PVC film offers unparalleled protection for sensitive pharmaceutical products, with moisture vapor transmission rates (MVTR) as low as 0.1 g/m²/day and oxygen transmission rates (OTR) below 0.5 cm³/m²/day. These exceptional barrier properties ensure product stability and extend shelf life significantly compared to conventional packaging materials.
The global medical packaging market has experienced substantial growth, with cold PVC film representing a significant segment valued at over $3.5 billion in 2024. The pharmaceutical industry's increasing focus on patient safety, combined with the rising prevalence of chronic diseases requiring long-term medication, has driven demand for high-performance packaging solutions. Asia-Pacific regions, particularly China and India, have emerged as major manufacturing hubs for cold PVC film production, leveraging advanced technology and cost-effective production capabilities.
Regulatory compliance remains a critical driver in the medical cold PVC film market. Stringent guidelines from agencies such as the FDA, EMA, and WHO mandate rigorous testing and validation of packaging materials. Manufacturers like Jiangsu Dahai Plastics Co., Ltd. have invested heavily in CNAS-accredited laboratories and quality control systems to ensure their products meet these exacting standards. The company's commitment to quality is evidenced by their comprehensive testing protocols, including extractables and leachables studies, biocompatibility assessments, and stability testing under various environmental conditions.
Blister packaging represents the most widespread application of cold PVC film in the pharmaceutical sector. This packaging format provides individual dose protection, tamper evidence, and excellent product visibility. Cold-formed blister packs are particularly suited for moisture-sensitive medications, including antibiotics, cardiovascular drugs, and hormonal therapies. The deep-draw capability of cold PVC film allows for the packaging of larger tablets, capsules, and even medical devices such as syringes and diagnostic test strips.
The pharmaceutical industry has witnessed a shift toward unit-dose packaging, driven by patient compliance initiatives and hospital pharmacy automation systems. Cold PVC film's compatibility with high-speed automated packaging lines makes it ideal for large-scale production while maintaining product integrity. Advanced printing technologies enable the incorporation of QR codes, serialization data, and anti-counterfeiting features directly onto the cold PVC film surface, enhancing supply chain security and traceability.
Exceptional moisture and oxygen resistance ensuring pharmaceutical product stability
Meets USP Class VI, ISO 15378, and international pharmaceutical standards
Optimal material utilization with minimal waste in high-volume production
Beyond pharmaceutical applications, cold PVC film has found extensive use in medical device packaging. Surgical instruments, diagnostic equipment, implantable devices, and sterile medical supplies all benefit from the protective properties of cold PVC film. The material's ability to withstand various sterilization methods, including ethylene oxide (EtO), gamma radiation, and electron beam sterilization, makes it versatile for different device categories.
Implantable medical devices such as cardiac stents, orthopedic implants, and neurostimulation devices require packaging that maintains sterility while protecting against mechanical damage during transportation and storage. Cold PVC film's puncture resistance and cushioning properties provide dual-layer protection, ensuring device integrity from manufacturing facility to operating room. The transparent PVC layer allows for visual inspection without compromising the sterile barrier, a critical feature for quality assurance protocols.
The medical packaging industry is experiencing a paradigm shift toward sustainable and environmentally responsible materials. While traditional cold PVC film offers excellent performance characteristics, manufacturers are investing in research and development of recyclable and bio-based alternatives. Innovations in PVC formulations incorporating renewable plasticizers and the development of mono-material structures that facilitate recycling represent significant areas of focus.
Smart packaging technologies are being integrated with cold PVC film systems, creating intelligent packaging solutions that monitor product conditions throughout the supply chain. Temperature-sensitive indicators, time-temperature integrators, and RFID tags embedded within or attached to cold PVC blister packs provide real-time data on storage conditions, helping to prevent medication spoilage and ensuring cold-chain integrity for temperature-sensitive biologics and vaccines.
The convergence of cold PVC film manufacturing with Industry 4.0 technologies is transforming production efficiency and quality control. Advanced sensor systems, artificial intelligence-driven defect detection, and predictive maintenance algorithms are being implemented in modern production facilities, reducing waste and improving consistency in film properties.
Medical-grade cold PVC film typically ranges in thickness from 60 to 300 microns, with the aluminum layer contributing 20-45 microns to the total structure. The forming depth capability varies from 2mm to 15mm, depending on the specific formulation and laminate structure. Tensile strength values typically exceed 40 N/15mm in both machine and transverse directions, ensuring robust package integrity during handling and transportation.
Seal strength is a critical parameter for pharmaceutical packaging, with medical-grade cold PVC film achieving seal strengths of 20-40 N/15mm when heat-sealed to appropriate lidding materials. The material exhibits excellent formability at room temperature, with elongation at break values ranging from 30% to 60%, allowing for complex geometries without compromising barrier properties or structural integrity.
Comprehensive quality assurance is paramount in medical packaging production. Jiangsu Dahai Plastics Co., Ltd. employs state-of-the-art testing equipment including universal testing machines for mechanical property evaluation, Agilent GC analyzers for residual solvent analysis, and specialized equipment for barrier property measurement. The company's CNAS-accredited laboratory conducts extractables and leachables studies following ICH Q3C and USP guidelines, ensuring patient safety and regulatory compliance.
Biocompatibility testing according to ISO 10993 standards is conducted on all medical-grade cold PVC film products. This includes cytotoxicity testing, sensitization studies, and irritation assessments to verify that the material is safe for contact with pharmaceutical products and, indirectly, with patients. Stability studies under accelerated conditions (40°C/75% RH) and long-term conditions (25°C/60% RH) validate the protective performance of the packaging throughout the product's intended shelf life.
The production of medical-grade cold PVC film requires sophisticated manufacturing capabilities and stringent quality management systems. Leading manufacturers operate cleanroom facilities with controlled environmental conditions to prevent contamination during production. Multi-layer extrusion and lamination processes are conducted under ISO Class 8 cleanroom conditions, with inline quality monitoring systems ensuring consistent product specifications.
Supply chain resilience has become increasingly important in the medical packaging sector, particularly following disruptions experienced during the COVID-19 pandemic. Manufacturers are diversifying their raw material sources and implementing strategic inventory management practices to ensure continuous supply to pharmaceutical companies. Dahai Plastics' extensive production capacity of over 100,000 tons annually positions the company as a reliable partner for both domestic and international pharmaceutical manufacturers.
The diversity of pharmaceutical products necessitates customized packaging solutions. Cold PVC film can be tailored in terms of thickness, barrier properties, color, and printing to meet specific product requirements. For photosensitive medications, amber-tinted PVC layers provide UV protection while maintaining visibility. For hygroscopic drugs, enhanced aluminum barrier layers minimize moisture ingress to levels below 0.05 g/m²/day.
Collaborative development partnerships between packaging manufacturers and pharmaceutical companies have become standard practice in the industry. These partnerships involve early-stage consultation on packaging design, material selection, and compatibility testing, ensuring optimal protection for new drug formulations. Dahai Plastics' technical team works closely with clients to develop custom solutions that balance performance requirements with cost considerations and sustainability objectives.
The cold PVC film market for medical applications is characterized by steady growth projections, with compound annual growth rates (CAGR) estimated at 5-7% through 2030. This growth is driven by expanding pharmaceutical production in emerging markets, increasing generic drug manufacturing, and the rising prevalence of chronic diseases requiring long-term medication regimens. The shift toward unit-dose packaging in hospital settings and the growth of e-pharmacy channels further contribute to market expansion.
Price dynamics in the cold PVC film market are influenced by raw material costs, particularly PVC resin and aluminum foil. Manufacturers with vertically integrated supply chains and long-term raw material contracts can offer more stable pricing to pharmaceutical customers. The economies of scale achieved by large-scale producers like Dahai Plastics enable competitive pricing while maintaining high quality standards, making medical-grade packaging accessible to pharmaceutical companies of all sizes.
The medical packaging industry faces increasing pressure to address environmental concerns associated with plastic packaging materials. While the protective performance of cold PVC film is unmatched, manufacturers are exploring various strategies to minimize environmental impact. These include optimizing material thickness to reduce overall plastic usage, developing recycling programs for post-industrial waste, and researching alternative materials that maintain performance while improving end-of-life options.
Life cycle assessment (LCA) studies are being conducted to quantify the environmental footprint of cold PVC film packaging compared to alternative materials. These studies consider factors including raw material extraction, manufacturing energy consumption, transportation impacts, and end-of-life disposal or recycling. The results inform sustainable packaging strategies and help pharmaceutical companies make evidence-based decisions regarding packaging material selection.
Jiangsu Dahai Plastics Co., Ltd. was founded in 1996, is a professional production of various types of PVC film and printing PVC film technology of private enterprises. We mainly produce super transparent film, ordinary transparent film, toy film, bath film, raincoat film, electrical tape film, cold film, non-stick film, decorative film, PEVA film, particles, tablecloth, shower curtain, urine bag.
The company has more than 20 production lines, more than 450 employees, of which 30% are technical management personnel, and has a sound management system. Covers an area of more than 120,000 square meters, annual output of more than 100,000 tons, annual sales of more than 1 billion. The company continues to introduce advanced production equipment and technology. The product quality reaches the international standard, the company's products not only sell well in the domestic market, but also exported to South America, Southeast Asia, Africa and other places.
We possess laboratories accredited by China National Commission for Conformity Assessment (CNAS), which are equipped with many kinds of world advanced experimental equipment and physical and chemical testing-analysis instruments. In every experiment, in every test, even the slightest difference can be detected by our machines, which greatly guarantees the quality of our products.
DAHAI continues to invest resources, and we will work with university teams to develop products. Our technical department is constantly learning new technologies and combining them with our own situation, through which our ability to innovate is keeping improving.
The total registered capital of several projects under the company group is 40 million dollar, total assets reach 140 million dollar, floor area is more than 120000sqm, with 20 imported environmental protection production lines, with an annual production capacity of 150,000 tons. In year 2018, we achieved sales of 180 million dollar, of which exports earned 10 million US dollars. The products are sold to more than 400 cities in 12 provinces and regions across the country, the market share ranks first among private enterprises in the province, and the products are exported to more than 10 countries and regions. In view of the market development trend and the future development of the company, it is proposed to build an intelligent manufacturing project of new medical materials.
20 eco-friendly production lines
150,000 tons annual capacity
120,000+ sqm operational footprint
$40M registered capital
Make green materials, create a good and healthy life!
To become the domestic polymer material application industry leader, to build a world-class brand!
Independent innovation intelligent future! Team style: people-oriented safety first!
Integrity, pragmatic, efficient, win-win!
Tongzhou Huaming Plastic Co., Ltd. was established.
Tongzhou Huaming Plastics Co., Ltd. was changed to Jiangsu Dahai Plastics Co., LTD.
Nantong Runyang Plastic Co., Ltd. was established.
Dahai Real Estate Development Co., Ltd. was established.
Field E-commerce company is established.
Jiangyin Zhonglian Real Estate company was established.
Jiangyin Huayue Real Estate Development Co., Ltd. was established.
Jiangsu Houbang Industrial Co., LTD.
We import all kinds of testing machines, such as universal testing machines, Agilent GC analyzers, gloss meters and cold-tolerance testing machines. Besides, we establish good cooperation with professional testing companies to meet customer's requirements. All of our products can meet the requirements of EN-71, ASTM-F-963, Model Toxics in Packaging Legislation (CONEG) and RoHS.
Complete realization from concept to market. Dahai Plastic assists customers around the world in developing and manufacturing products for packaging, medical supplies, building materials, toy supplies etc.
Our dedicated sales and technical teams engage closely with customers to gather detailed specifications, discuss project goals, and identify any unique challenges.
Once the needs are confirmed, we move into the product proofing phase. During this stage, we create prototypes or samples based on the agreed-upon specifications.
After thorough evaluation and refinement, we finalize the sample that both parties agree upon. The confirmed sample serves as the benchmark for all subsequent production runs.
Our make-to-order approach allows us to tailor our production processes to meet individual client needs. Leveraging our flexible manufacturing capabilities.
Upon completion of production, each item undergoes a comprehensive finished inspection. Our quality assurance team employs advanced testing methods.
We actively seek feedback to continuously improve our services and adapt to evolving market demands. Through ongoing partnerships, we aim to be more than just a supplier.
